U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUINIDINE

SMILES

[H][C@@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3

InChI

InChIKey=LOUPRKONTZGTKE-LHHVKLHASA-N
InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1

HIDE SMILES / InChI
Molecular Formula C20H24N2O2
Molecular Weight 324.4168
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17506538 | https://www.ncbi.nlm.nih.gov/pubmed/22761000 | https://www.ncbi.nlm.nih.gov/pubmed/22512909 | https://www.ncbi.nlm.nih.gov/pubmed/21832259

Quinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. It is a stereoisomer of quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. Like all other class I antiarrhythmic agents, quinidine primarily works by blocking the fast inward sodium current (INa). Quinidine's effect on INa is known as a 'use-dependent block'. This means at higher heart rates, the block increases, while at lower heart rates, the block decreases. The effect of blocking the fast inward sodium current causes the phase 0 depolarization of the cardiac action potential to decrease (decreased Vmax). Quinidine also blocks the slowly inactivating, tetrodotoxin-sensitive Na current, the slow inward calcium current (ICA), the rapid (IKr) and slow (IKs) components of the delayed potassium rectifier current, the inward potassium rectifier current (IKI), the ATP-sensitive potassium channel (IKATP) and Ito. Quinidine is also an inhibitor of the cytochrome P450 enzyme 2D6 and can lead to increased blood levels of lidocaine, beta blockers, opioids, and some antidepressants. Quinidine also inhibits the transport protein P-glycoprotein and so can cause some peripherally acting drugs such as loperamide to have central nervous system side effects, such as respiratory depression if the two drugs are coadministered. Quinidine can cause thrombocytopenia, granulomatous hepatitis, myasthenia gravis, and torsades de pointes, so is not used much today. Torsades can occur after the first dose. Quinidine-induced thrombocytopenia (low platelet count) is mediated by the immune system and may lead to thrombocytic purpura. A combination of dextromethorphan and quinidine has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis. This drug is marketed as Nuedexta in the United States. Intravenous quinidine is also indicated for the treatment of Plasmodium falciparum malaria. However, quinidine is not considered the first-line therapy for P. falciparum. The recommended treatments for P. falciparum malaria, according to the Toronto Notes 2008, are a combination of either quinine and doxycycline or atovaquone and proguanil (Malarone). The drug is also effective for the treatment of atrial fibrillation in horses.

CNS Activity

Originator

Approval Year

1921
1447
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 7300.0 nM [IC50]
Inhibitor
8146
 6900.0 nM [IC50]
Inhibitor
8146
 2200.0 nM [IC50]
Inhibitor
8146
 19820.0 nM [IC50]
Inhibitor
8146
Inhibitor
8146
 18.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
QUINIDINE GLUCONATE

Approved Use

Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. DOSAGE AND ADMINISTRATION Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. The increased risk of death should specifically be considered. Quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inadequate. e.g., In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia during therapy, and a single recurrence should not be interpreted as therapeutic failure. will recur Suppression of ventricular arrhythmias Quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise. Antiarrhythmic drugs (including quinidine sulfate) have not been shown to enhance survival in patients with ventricular arrhythmias. Treatment of malaria Quinidine sulfate is also indicated in the treatment of life-threatening malaria. Plasmodium falciparum

Launch Date

-6.1456318E11
Primary
Approved
8307
QUINIDINE GLUCONATE

Approved Use

Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. DOSAGE AND ADMINISTRATION Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. The increased risk of death should specifically be considered. Quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inadequate. e.g., In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia during therapy, and a single recurrence should not be interpreted as therapeutic failure. will recur Suppression of ventricular arrhythmias Quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise. Antiarrhythmic drugs (including quinidine sulfate) have not been shown to enhance survival in patients with ventricular arrhythmias. Treatment of malaria Quinidine sulfate is also indicated in the treatment of life-threatening malaria. Plasmodium falciparum

Launch Date

-6.1456318E11
Primary
Approved
8307
QUINIDINE GLUCONATE

Approved Use

Conversion of atrial fibrillation/flutter In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. If this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. DOSAGE AND ADMINISTRATION Reduction of frequency of relapse into atrial fibrillation/flutter Chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. The increased risk of death should specifically be considered. Quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inadequate. e.g., In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia during therapy, and a single recurrence should not be interpreted as therapeutic failure. will recur Suppression of ventricular arrhythmias Quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise. Antiarrhythmic drugs (including quinidine sulfate) have not been shown to enhance survival in patients with ventricular arrhythmias. Treatment of malaria Quinidine sulfate is also indicated in the treatment of life-threatening malaria. Plasmodium falciparum

Launch Date

-6.1456318E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.4 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/512840/
3.74 mg/kg single, oral
dose: 3.74 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUINIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.8 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/512840/
3.74 mg/kg single, oral
dose: 3.74 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUINIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/512840/
3.74 mg/kg single, oral
dose: 3.74 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUINIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf
202 mg single, oral
dose: 202 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUINIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
12%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/089338s036lbl.pdf
202 mg single, oral
dose: 202 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
QUINIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 4 times / day multiple, oral
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1269875
unhealthy, 47 years
n = 1
Health Status: unhealthy
Age Group: 47 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1269875
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Sources:
https://pubmed.ncbi.nlm.nih.gov/1269875
324 mg 5 times / day multiple, oral
Dose: 324 mg, 5 times / day
Route: oral
Route: multiple
Dose: 324 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
unhealthy, 56 yeras
n = 1
Health Status: unhealthy
Age Group: 56 yeras
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
Disc. AE: Myalgia...
AEs leading to
discontinuation/dose reduction:
Myalgia (severe, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
4 g single, oral
Overdose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
healthy, 57 years
n = 1
Health Status: healthy
Age Group: 57 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
Other AEs: Grand mal convulsion, Cardiotoxicity...
Other AEs:
Grand mal convulsion (1 patient)
Cardiotoxicity (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
324 mg 3 times / day multiple, oral
Dose: 324 mg, 3 times / day
Route: oral
Route: multiple
Dose: 324 mg, 3 times / day
Co-administed with::
digoxin
levothyroxine sodium
crystalline warfarin sodium
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
Disc. AE: Drug-induced lupus erythematosus...
AEs leading to
discontinuation/dose reduction:
Drug-induced lupus erythematosus (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
370 mg 6 times / day multiple, oral
Highest studied dose
Dose: 370 mg, 6 times / day
Route: oral
Route: multiple
Dose: 370 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
healthy, > 23 years
n = 1
Health Status: healthy
Age Group: > 23 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
1650 mg single, intravenous
Dose: 1650 mg
Route: intravenous
Route: single
Dose: 1650 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
healthy, > 23 years
n = 1
Health Status: healthy
Age Group: > 23 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
Sources:
https://pubmed.ncbi.nlm.nih.gov/6747817
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity Disc. AE
200 mg 4 times / day multiple, oral
Dose: 200 mg, 4 times / day
Route: oral
Route: multiple
Dose: 200 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1269875
unhealthy, 47 years
n = 1
Health Status: unhealthy
Age Group: 47 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1269875
Myalgia severe, 1 patient
Disc. AE
324 mg 5 times / day multiple, oral
Dose: 324 mg, 5 times / day
Route: oral
Route: multiple
Dose: 324 mg, 5 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
unhealthy, 56 yeras
n = 1
Health Status: unhealthy
Age Group: 56 yeras
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
Cardiotoxicity 1 patient
4 g single, oral
Overdose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
healthy, 57 years
n = 1
Health Status: healthy
Age Group: 57 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
Grand mal convulsion 1 patient
4 g single, oral
Overdose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
healthy, 57 years
n = 1
Health Status: healthy
Age Group: 57 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/5557506
Drug-induced lupus erythematosus 1 patient
Disc. AE
324 mg 3 times / day multiple, oral
Dose: 324 mg, 3 times / day
Route: oral
Route: multiple
Dose: 324 mg, 3 times / day
Co-administed with::
digoxin
levothyroxine sodium
crystalline warfarin sodium
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7604299
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532

inducer
753
substrate
985

inhibitor
1695
substrate
1168

inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1401

OCT1
498

OCT2
630

OCT3
143

MATE1
302

MATE2
259

CYP1A2
1463

CYP2A6
670

CYP2B6
770

CYP2C8
869

CYP2C19
1410

CYP2E1
846
OCTN1
47

OCTN2
50

P-gp
1491

CYP2E1
633
CYP1A2
671

CYP2B6
521
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1620
 no
CYP1A2
1620
 no
CYP2A6
702
 no
CYP2B6
946
 no
CYP2B6
946
 no
CYP2C19
1484
 no
CYP2C8
923
 no
CYP2C9
1747
 no
CYP2E1
929
 no
CYP3A4
1857
 no
CYP3A4
1857
 no
CYP2D6
1826
 yes [IC50 0.051 uM]
likely (co-administration study)
Comment: Caution must be exercixed whenever quinidine is prescribed together with drugs metabolized by CYP2C6.
Page: 5.0
OCT3
143
 yes [IC50 18.3 uM]
OCT1
513
 yes [IC50 5.7 uM]
OCT2
631
 yes [IC50 8.7 uM]
P-gp
1588
 yes [IC50 9.52 uM]
MATE2
259
 yes [Ki 23.1 uM]
MATE1
304
 yes [Ki 29.2 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
985
 minor
CYP2D6
1168
 no
CYP2E1
633
 no
OCTN1
47
 yes
OCTN2
50
 yes
P-gp
1491
 yes
CYP3A4
1670
 yes
likely (co-administration study)
Comment: coadministration of quinidine causes variable slowing of the metabolism of nifedipine. Interactions with other dihydropyridine calcium channel blockers have not been reported, but these agents (including felodipine, nicardipine, and nimodipine) are all dependent upon P450IIIA4 for metabolism, so similar interactions with quinidine should be anticipated
Page: 2.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
AEchem Scientific Corp., USA
AE020240
http://www.aechemsc.com/info_products/AE020240.php
AK Scientific, Inc. (AKSCI)
6566AF
http://www.aksci.com/item_detail.php?cat=6566AF
AK Scientific, Inc. (AKSCI)
66338
http://www.aksci.com/item_detail.php?cat=66338
Aaron Chemicals
AR003696
http://www.aaronchem.com/56-54-2
AbMole Bioscience
M3406
http://www.abmole.com/products/quinidine.html
Acadechem
ACDS-067325
http://www.acadechemical.com/product/142024
Achemtek
0104-024048
http://www.achemtek.com/56-54-2
Acorn PharmaTech
ACN-052225
http://www.acornpharmatech.com/
Acros Organics
AC163680250
https://www.fishersci.com/shop/products/quinidine-98-anhydrous-acros-organics-1/AC163680250
Acros Organics
AC163681000
https://www.fishersci.com/shop/products/quinidine-98-anhydrous-acros-organics/AC163681000
Alfa Aesar
A12559
https://www.alfa.com/en/catalog/A12559/
Alfa Chemistry
AP56542-A
https://reagents.alfa-chemistry.com/product/quinidine-cas-56-54-2-13236.html
Alfa Chemistry
AP56542-B
https://reagents.alfa-chemistry.com/product/quinidine-cas-56-54-2-13237.html
Alfa Chemistry
ACM56542
https://www.alfachemic.com/catalysts/product/quinidine-cas-56-54-2-180968.html
Alfa Chemistry
56-54-2
https://www.alfachemic.com/catalysts/quinidine-cas-56-54-2-item-180968.htm
Ambinter
Amb17835341
http://www.ambinter.com/reference/17835341
AstaTech, Inc.
23083
http://www.astatechinc.com/CPSResult.php?CRNO=26833
Aurora Fine Chemicals LLC
A24.073.679
http://online.aurorafinechemicals.com/info?ID=A24.073.679
Aurum Pharmatech LLC
M-7594
http://www.Aurumpharmatech.com/Product/ProductDetails/M_7594
Avantor Inc
BT127895-1G
https://us.vwr.com/store/product/16900231/quinidine
Avantor Inc
BT127895-25G
https://us.vwr.com/store/product/16900231/quinidine
Avantor Inc
BT127895-5G
https://us.vwr.com/store/product/16900231/quinidine
BLD Pharm
BD01139139
http://www.bldpharm.com/products/56-54-2.html
BLD Pharm
BD150056
http://www.bldpharm.com/products/56-54-2.html
BLD Pharm
BD01094112
http://www.bldpharm.com/products/66591-62-6.html
BioCrick
BCC7863
http://www.biocrick.com/Quinidine-BCC7863.html
BioSynth
W-109256
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-109256.html
CSNpharm
CSN11818
https://www.csnpharm.com/products/quinidine.html
Capot Chemical
7994
http://www.capotchem.com/en/7994.htm
Capot Chemical
PubChem7994
http://www.capotchem.com/en/7994.htm
Chem Scene
CS-7812
http://www.chemscene.com/56-54-2.html
ChemMol
1030683
http://www.chemmol.com/chemmol/1030683.html
ChemMol
99106903
http://www.chemmol.com/chemmol/99106903.html
Chemenu
CM108220
http://www.chemenu.com/products/CM108220
Chemspace
CSSB00016988638
https://chem-space.com/CSSB00016988638
DC Chemicals
DC9066
http://www.dcchemicals.com/product_show-Quinidine.html
Glentham Life Sciences
GE1634
http://www.glentham.com/products/product/GE1634/
Huateng Pharma
F94507
https://en.huatengsci.com/products/intermediates/
LGC Standards
LGCFOR1523.01
https://www.lgcstandards.com/US/en/p/LGCFOR1523.01
LGC Standards
MM1523.01
https://www.lgcstandards.com/US/en/p/MM1523.01
Lab Network
LN00173655
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00173655
Lab Network
LN01747538
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01747538
Matrix Scientific
75925
https://www.matrixscientific.com/075925.html
MedChem Express
HY-B1751
https://www.medchemexpress.com/Quinidine.html
MuseChem
R007506
https://www.musechem.com/product/R007506.html
Oakwood
79244
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64418&ExtHyperLink=1
Parchem
45359
https://www.parchem.com/chemical-supplier-distributor/(1S)-(6-Methoxyquinolin-4-yl)((2R-4S-5R)-5-vinylquinuclidin-2-yl)methanol-045359.aspx
R&D Chemicals
611
http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8191
Sigma-Aldrich
22600_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/22600?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Q3625_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/q3625?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S752224
https://www.smolecule.com/products/s752224
VladaChem
VL144107
https://www.vladachem.com/product.php?products=56-54-2
VladaChem
VL267661-25G
https://www.vladachem.com/product.php?products=56-54-2
VladaChem
VL270184-25G
https://www.vladachem.com/product.php?products=56-54-2
abcr GmbH
AB121200
http://www.abcr.com/shop/en/AB121200
eNovation Chemicals
D378950
http://www.enovationchem.com/productDetails.asp?productID=D378950
eNovation Chemicals
D593773
https://enovationchem.com/ProductDetails.asp?ProductID=D593773
eNovation Chemicals
D674705
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674705
eNovation Chemicals
D766047
https://www.enovationchem.com/ProductDetails.asp?ProductID=D766047
iChemical
EBD2202687
http://www.ichemical.com/products/56-54-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-7178915526
https://mcule.com/MCULE-7178915526/
PubMed

PubMed

TitleDatePubMed
Metabolism of 3-methylindole by porcine liver microsomes: responsible cytochrome P450 enzymes.
2000 Jun
TASK-3, a new member of the tandem pore K(+) channel family.
2000 Mar 31
[Congenital myasthenic syndrome (CMS) caused by postsynaptic defects].
2001
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
2001
Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes.
2001
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis.
2001 Aug
Sympathetic activation enhances QT prolongation by quinidine.
2001 Jan
Salt and cosolvent effects on ionic drug loading into microspheres using an O/W method.
2001 Jan 29
Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions.
2001 Jun
Mechanical effects of liriodenine on the left ventricular-arterial coupling in Wistar rats: pressure-stroke volume analysis.
2001 May
Coumarin substrates for cytochrome P450 2D6 fluorescence assays.
2001 May 15
An amino acid residue whose change by mutation affects drug binding to the HERG channel.
2001 Oct 12
Patents

Patents

JP2000516204A
66
JP2001500477A
122
JP2002500227A
42
JP2002511777A
401
JP2002526510A
46
JP2003508349A
45
JP2004002384A
19
JP2004520398A
36
JP2004521939A
18
JP2005306882A
18
JP2005526546A
32
JP2005537891A
13
JP2005538090A
27
JP2006503898A
40
JP2006514009A
43
JP2006514917A
60
JP2009526755A
434
JP2009527289A
25
JP2009531466A
72
JP2010520238A
15
JP2011225601A
13
JP2011506398A
20
JP2011507800A
47
JP2011513484A
29
JP2011524365A
29
JP2012500844A
19
JP4097285B2
16
JP4653399B2
50
JP4708327B2
43
JP4732696B2
66
JP4744875B2
29
JP4825129B2
15
JPH00873355A
15
JPH01187039A
13
JPH02157223A
13
JPH02255617A
13
JPH04198159A
13
JPH0616552A
13
JPH0665133A
19
JPH08325266A
13
JPH0873355A
21
JPH10251241A
13
JPS55162743A
19
JPS5535060A
13
JPS56123965A
13
JPS57175190A
13
JPS5815975A
13
JPS58183684A
13
JPS60169460A
13
JPS60169462A
13
JPS6190057A
13

Sample Use Guides

In Vivo Use Guide
Tablet (sulfate):100 to 600 mg/dose orally every 4 to 6 hours; begin at 200 mg/dose and titrate to desired effect (maximum daily dose: 3 to 4 g). Extended Release: 324 to 648 mg (gluconate) orally every 8 to 12 hours or 300 to 600 mg (sulfate) orally every 8 to 12 hours. IV: 800 mg of quinidine gluconate diluted to 50 mL and given at a rate not to exceed 1 mL/min.
Route of Administration: Other
In Vitro Use Guide
Rat brain pericytes were plated onto the backside of 12-well Transwell filters (pore size: 0.4 μm; 1.5 × 104 cells/filter). The next day, endothelial cells were plated onto the upper surface of the filters. After reaching confluency, the endothelial monolayer was supplied with 550 nM hydrocortisone, 250 μM CPT-cAMP, and 17.5 μM RO-201724 and placed into dishes containing glial cultures for 24 h. Transwell filters containing endothelial cells and pericytes were removed from the plates containing the glial culture. Filters were washed with Ringer-HEPES solution (pH 7.4). Quinidine or digoxin was applied at final concentrations of 0.1 μM and 10 μM, respectively. Radiolabeled quinidine and digoxin as tracers were also added to the radioactive concentration of 1 μCi/mL. The inhibitors were added together with the test compound at final concentrations of 1 μM (LY- 335979 and PSC-833) or 100 μM (quinidine). Samples were taken from the basolateral or apical side, respectively, at 15, 30, and 60 min, and radioactivity was measured using a liquid scintillation counter
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:38:44 UTC 2022
Edited
by admin
on Fri Dec 16 16:38:44 UTC 2022
Record UNII
ITX08688JL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUINIDINE
HSDB   MART.   MI   VANDF   WHO-DD  
Common Name English
(+)-QUINIDINE
Common Name English
(9S)-6'-METHOXYCINCHONAN-9-OL
Systematic Name English
QUINIDINE [MART.]
Common Name English
.BETA.-QUINIDINE
Common Name English
CONQUININE
Common Name English
QUININE SULFATE IMPURITY A [EP IMPURITY]
Common Name English
CINCHONAN-9-OL, 6'-METHOXY-, (9S)-
Common Name English
Quinidine [WHO-DD]
Common Name English
QUININE HYDROCHLORIDE IMPURITY A [EP IMPURITY]
Common Name English
(8R,9S)-QUINIDINE
Common Name English
QUINIDINE [VANDF]
Common Name English
(S)-((2S,4S,5R)-5-ETHENYL-1-AZABICYCLO(2.2.2)OCT-2-YL)(6-METHOXYQUINOLIN-4-YL)METHANOL
Systematic Name English
QUININE BISULFATE IMPURITY A [WHO-IP]
Common Name English
QUININE BISULFATE HEPTAHYDRATE IMPURITY A [WHO-IP]
Common Name English
PITAYINE
Common Name English
QUININE SULFATE IMPURITY A [WHO-IP]
Common Name English
QUINIDINE [HSDB]
Common Name English
QUINIDINE [MI]
Common Name English
KINIDIN
Common Name English
Classification Tree Code System Code
WHO-VATC QC01BA01
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
WHO-ATC C01BA01
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
WHO-ATC C01BA71
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
NDF-RT N0000175426
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
WHO-VATC QC01BA51
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
NDF-RT N0000182135
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
LIVERTOX NBK548869
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
WHO-VATC QC01BA71
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
WHO-ATC C01BA51
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
Code System Code Type Description
DRUG BANK
DB00908
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
RXCUI
9068
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY RxNorm
LACTMED
Quinidine
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
NDF-RT
N0000182137
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
EVMPD
SUB04166MIG
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
MESH
D011802
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY
IUPHAR
2342
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
PUBCHEM
441074
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY
DAILYMED
ITX08688JL
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
WIKIPEDIA
QUINIDINE
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY
MERCK INDEX
M9446
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY Merck Index
HSDB
225
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
EPA CompTox
DTXSID4023549
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
ChEMBL
CHEMBL1294
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
ECHA (EC/EINECS)
200-279-0
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
CHEBI
28593
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
DRUG CENTRAL
2346
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
NCI_THESAURUS
C793
Created by admin on Fri Dec 16 16:38:45 UTC 2022 , Edited by admin on Fri Dec 16 16:38:45 UTC 2022
PRIMARY
CAS
56-54-2
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
FDA UNII
ITX08688JL
Created by admin on Fri Dec 16 16:38:44 UTC 2022 , Edited by admin on Fri Dec 16 16:38:44 UTC 2022
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
OCTN-1
TRANSPORTER -> SUBSTRATE
OCT-2
TRANSPORTER -> INHIBITOR
Structure of QUINIDINE DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
OCT-1
TRANSPORTER -> SUBSTRATE
OCT-1
TRANSPORTER -> INHIBITOR
Structure of QUINIDINE GLUCONATE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D15 (CANINE)
METABOLIC ENZYME -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
OCT-3
TRANSPORTER -> INHIBITOR
MATE-2
TRANSPORTER -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of QUINIDINE SULFATE
SALT/SOLVATE -> PARENT
Structure of QUINIDINE LACTATE
SALT/SOLVATE -> PARENT
OCTN-1
TRANSPORTER -> INHIBITOR
Structure of QUINIDINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of QUINIDINE HEMIPENTAHYDRATE
SOLVATE->ANHYDROUS
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
POTENT
OCTN-2
TRANSPORTER -> SUBSTRATE
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
Structure of QUINIDINE BISULFATE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Related Record Type Details
Structure of QUINIDINE N-OXIDE
METABOLITE -> PARENT
MAJOR
Structure of 3-HYDROXYQUINIDINE
METABOLITE LESS ACTIVE -> PARENT
Metabolite to parent drug ratio in non-uraemic human plasma.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
Structure of 3-HYDROXYQUINIDINE
METABOLITE LESS ACTIVE -> PARENT
quinidine is metabolized by CYP3A4 (In vitro)
Structure of LNC-834 FREE BASE
METABOLITE -> PARENT
Structure of 3-HYDROXYQUINIDINE
METABOLITE LESS ACTIVE -> PARENT
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
Structure of QUININE HYDROCHLORIDE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of QUININE BISULFATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of QUININE BISULFATE HEPTAHYDRATE
PARENT -> IMPURITY
Not Specified
Structure of QUININE SULFATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of QUINIDINE SULFATE
PARENT -> IMPURITY
Not Specified
Structure of QUININE SULFATE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Related Record Type Details
Structure of QUINIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC Heart Failure
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966